Psoriasis vulgaris und Komorbiditäten

Zusammenfassung

Die Psoriasis vulgaris ist eine chronisch-entzündliche Hauterkrankung mit einer Inzidenz von 2 – 3 % in den industrialisierten Ländern. 20 – 30 % der Psoriasis-Patienten erkranken im Laufe des Lebens auch an einer Psoriasis-Arthritis. Auch chronisch-entzündliche Darmerkrankungen, Depression, Alkohol- und Nikotinabusus sind gehäuft mit Psoriasis assoziiert. Besonderes Augenmerk sollte auf Erkrankungen des kardiovaskulären und metabolischen Formenkreises gelegt werden. Die Diagnostik und Therapie der Begleiterkrankungen erfordert eine enge interdisziplinäre Zusammenarbeit zwischen Dermatologen, Rheumatologen, Allgemeinmedizinern, Internisten und bisweilen Ophthalmologen. Viele Patienten nehmen unabhängig von der Psoriasis Medikamente ein, die mit der Psoriasis-Therapie interferieren können. Eine effektive Behandlung der Psoriasis und Psoriasis-Arthritis kann möglicherweise das Risiko für die Begleiterkrankungen und Mortalität senken.

Abstract

Psoriasis is a chronic inflammatory skin disease affecting 2 – 3 % of the population in industrialized countries. 20 – 30 % of the patients additionally suffer from psoriatic arthritis. Besides, chronic inflammatory bowel disease, depression, alcohol abuse and smoking are associated with psoriasis. In recent years a number of epidemiological studies showed a substantial association of psoriasis with the metabolic syndrome. Duration and severity of psoriasis directly contribute to an increased cardiovascular risk and a higher mortality rate. Hence, physicians are challenged to seek for effective treatment modalities which not only improve the psoriasis but also take into account the relevant comorbidities. In this review the current knowledge of comorbidities in psoriasis patients is addressed and the impact of systemic treatment options is discussed.

Schlüsselwörter

Psoriasis vulgaris - Psoriasis-Arthritis - Komorbiditäten - Metabolisches Syndrom - Mortalität

Keywords

Psoriasis vulgaris - psoriatic arthritis - comorbidities - metabolic syndrome - mortality

Literatur

• 1 Azfar R S, Gelfand J M. Psoriasis and metabolic disease: epidemiology and pathophysiology.  Curr Opin Rheumatol. 2008;  20 (4) 416-422
• 2 Boehncke S, Thaci D, Beschmann H, Ludwig R J, Ackermann H, Badenhoop K, Boehncke W H. Psoriasis patients show signs of insulin resistance.  Br J Dermatol. 2007;  157 (6) 1249-1251
• 3 Boehncke W H, Boehncke S, Schon M P. Managing comorbid disease in patients with psoriasis.  Br Med J. 2010;  340 b5666
• 4 Boehncke W H, Buerger C, Boehncke S. [Co-morbidities in psoriasis vulgaris].  Hautarzt. 2009;  60 (2) 116-121
• 5 Cargill M, Schrodi S J, Chang M, Garcia V E, Brandon R, Callis K P. et al . A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.  Am J Hum Genet. 2007;  80 (2) 273-290
• 6 Duerr R H, Taylor K D, Brant S R, Rioux J D, Silverberg M S, Daly M J. et al . A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.  Science. 2006;  314 (5804) 1461-1463
• 7 Finlay A Y. Current severe psoriasis and the rule of tens.  Br J Dermatol. 2005;  152 (5) 861-867
• 8 Finlay A Y, Khan G K. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.  Clin Exp Dermatol. 1994;  19 (3) 210-216
• 9 Gelfand J M, Gladman D D, Mease P J, Smith N, Margolis D J, Nijsten T. et al . Epidemiology of psoriatic arthritis in the population of the United States.  J Am Acad Dermatol. 2005;  53 (4) 573
• 10 Gelfand J M, Neimann A L, Shin D B, Wang X, Margolis D J, Troxel A B. Risk of myocardial infarction in patients with psoriasis.  JAMA. 2006;  296 (14) 1735-1741
• 11 Gelfand J M, Troxel A B, Lewis J D, Kurd S K, Shin D B, Wang X. et al . The risk of mortality in patients with psoriasis: results from a population-based study.  Arch Dermatol. 2007;  143 (12) 1493-1499
• 12 Gerdes S, Mrowietz U. Impact of comorbidities on the management of psoriasis.  Curr Probl Dermatol. 2009;  38 21-36
• 13 Gerdes S, Zahl V A, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis.  Br J Dermatol. 2008;  159 (5) 1116-1123
• 14 Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.  J Eur Acad Dermatol Venereol. 2008;  22 (3) 341-344
• 15 Gottlieb A B, Dann F. Comorbidities in patients with psoriasis.  Am J Med. 2009;  122 (12) 1150-1159
• 16 Guenther L, Gulliver W. Psoriasis comorbidities.  J Cutan Med Surg. 2009;  13 Suppl 2 S77-S87
• 17 Johnston A, Arnadottir S, Gudjonsson J E, Aphale A, Sigmarsdottir A A, Gunnarsson S I. et al . Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation.  Br J Dermatol. 2008;  159 (2) 342-350
• 18 Kaplan M J. Cardiometabolic risk in psoriasis: differential effects of biologic agents.  Vasc Health Risk Manag. 2008;  4 (6) 1229-1235
• 19 Kerekes G, Soltesz P, Der H, Veres K, Szabo Z, Vegvari A. et al . Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis.  Ann N Y Acad Sci. 2009;  1173 814-821
• 20 Krause R. Ultraviolet B and blood pressure.  Lancet. 1998;  352 709-710
• 21 Ludwig R J, Boehncke W H. Psoriasis and risk of myocardial infarction.  JAMA. 2007;  297 (4) 362-363
• 22 Ludwig R J, Herzog C, Rostock A, Ochsendorf F R, Zollner T M, Thaci D. et al . Psoriasis: a possible risk factor for development of coronary artery calcification.  Br J Dermatol. 2007;  156 (2) 271-276
• 23 Nast A, Kopp I B, Augustin M, Banditt K B, Boehncke W H, Follmann M. et al . Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.  J Dtsch Dermatol Ges. 2007;  5 Suppl 3 1-119
• 24 Paiva E S, Macaluso D C, Edwards A, Rosenbaum J T. Characterisation of uveitis in patients with psoriatic arthritis.  Ann Rheum Dis. 2000;  59 (1) 67-70
• 25 Prodanovich S, Ma F, Taylor J R, Pezon C, Fasihi T, Kirsner R S. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.  J Am Acad Dermatol. 2005;  52 (2) 262-267
• 26 Qureshi A A, Dominguez P, Duffin K C, Gladman D D, Helliwell P, Mease P J, Husni M E. Psoriatic arthritis screening tools.  J Rheumatol. 2008;  35 (7) 1423-1425
• 27 Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study.  Arthritis Rheum. 2006;  54 (8) 2665-2673
• 28 Weinberg J M. More than skin deep.  Cutis. 2008;  82 (3) 175